-
公开(公告)号：EP4335459A1
公开(公告)日：2024-03-13
申请号：EP22807516.4
申请日：2022-05-11
IPC分类号： A61K47/68 , A61K9/08 , A61K9/19 , A61K38/46 , A61K39/395 , A61K47/02 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/26 , A61P3/00 , A61P25/00 , C12N15/13 , C12N15/56 , C12N15/62
摘要： Provided is a pharmaceutical composition for treatment of mucopolysaccharidosis type I patients. Here, the patient has a disorder particularly in the central nervous system. A pharmaceutical composition containing, as an active ingredient, a fusion protein of an anti-human transferrin receptor antibody and human α-L-iduronidase is administered to a patient with mucopolysaccharidosis type I by intravenous infusion at a dose of 0.1 to 10 mg/kg body weight. The administration is performed continually for at least 3 months at intervals of 5 days to 21 days. This decomposes dermatan sulfate and heparan sulfate accumulated in the tissues of the patient, particularly in the central nervous system.
-
公开(公告)号：EP3588090A1
公开(公告)日：2020-01-01
申请号：EP18757368.8
申请日：2018-02-20
发明人： TANAKA, Noboru , KIDA, Sachiho
摘要： [Problem] A method for measuring the amount of trace amo unts of heparan sulfate and/or dermatan sulfate containe d in a sample is provided.
[Solution] The present invention provides a method for decomposing heparan sulfate and dermatan sulfate contained in a sample into, respectively, a disaccharide in which uronic acid and amino sugar are α1,4-bonded and a disaccharide in which uronic acid and amino sugar are α1,3-bonded. More particularly, the present invention provides a method for decomposing heparan sulfate and dermatan sulfate by heating the heparan sulfate and the dermatan sulfate in, for example, 2,2-dimethoxypropane-containing methanol hydrochloride at 65-85°C for 80-180 minutes and 60-80°C for 20-100 minutes, respectively.
-
搜索结果
2 条记录 (耗时 0.009 秒)
